OPTIMAL phase III trial

PFS was significantly longer in erlotinib-treated Chinese patients with EGFR Mut+ NSCLC compared with that of patients treated with standard chemotherapy. Erlotinib was also better tolerated.1,2

Study design and endpoints1

  • OPTIMAL was a randomised phase III trial that took place across 22 centres in China. 
  • The trial compared erlotinib versus standard chemotherapy as first-line treatment for EGFR Mut+ NSCLC.

 

ECOG PS (Eastern Co-operative Oncology Group performance status)

Key Results

Efficacy2

Patients receiving erlotinib had longer PFS than patients receiving chemotherapy.

Safety1

Patients treated with erlotinib experienced fewer treatment related severe AEs, fewer grade 3/4 AEs and fewer dose reductions due to AEs than patients treated with chemotherapy.

Please click here for further safety data